Quick Overview.
GHRP-6 (Growth Hormone Releasing Peptide-6) is the first-generation synthetic hexapeptide in the GHRP family. It stimulates growth hormone release by binding to the ghrelin receptor (GHSR-1a) in the pituitary gland and hypothalamus. [1] GHRP-6 is less potent than GHRP-2 or Hexarelin for GH release, but it is the most potent hunger stimulant in the GHRP class — a property that can be either a benefit (for those seeking to increase caloric intake) or a significant drawback (for those on a caloric deficit). [2]
GHRP-6 was the first GHRP to be synthesised and studied, and it has the longest research history in the class. It is also notable for its potential gastroprotective properties, which have been studied in animal models. [3]
Who it is for:
- Those who want to increase appetite and caloric intake (e.g., hardgainers, bulking phases).
- Intermediate users seeking a moderate GH pulse with a well-studied safety profile.
- Those interested in the potential gastroprotective properties.
Who it is NOT for:
- Those on a caloric deficit or fat loss protocol (extreme hunger is a significant drawback).
- Beginners (Ipamorelin is a safer starting point).
- Tested athletes (banned by WADA).
Turn this protocol into your actual schedule.
Log every dose, every side-effect, and every PR on one timeline.
The Protocol & Usage Guide.
Before You Start: The Checklist
- Baseline Bloodwork: IGF-1, AM cortisol, prolactin, fasting glucose.
- Supplies: Insulin syringes (31G, 5/16"), bacteriostatic water, alcohol swabs.
- Reconstitution: Add 2 mL bacteriostatic water to a 2 mg vial = 1000 mcg/mL.
Standard Dosing Protocols
| Experience Level | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 100 mcg | 1-2x/day | Start here to assess hunger and cortisol response. community |
| Intermediate | 100-200 mcg | 2-3x/day | Most common community protocol. community |
| Advanced | 200 mcg | 3x/day | Diminishing returns above 200 mcg per injection. community |
Note: The intense hunger response from GHRP-6 is dose-dependent. Starting at 100 mcg allows users to assess their tolerance before increasing. community
Injection Timing & Fasting
- Inject on an empty stomach (2 hours fasted) for maximum GH pulse.
- Be prepared for intense hunger 15-30 minutes after injection.
- Best times: upon waking, pre-workout, or before bed.
Cycle Length
- Standard Cycle: 8 to 12 weeks. community
- Time Off: 4 to 8 weeks off between cycles. community
Missed Dose Protocol
Skip the missed dose and resume the next scheduled injection. Do not double dose.
Nutritional Support & Recommended Supplements.
Macronutrient Alignment
- Carbohydrates: Minimise around injection windows to prevent insulin blunting of GH pulse. However, the post-injection hunger window is an ideal time to consume a high-protein meal.
- Protein: 1.6-2.2 g/kg body weight to support IGF-1-driven anabolism.
- Caloric Surplus: GHRP-6 is best suited to bulking phases where the hunger response can be leveraged to increase caloric intake.
Micronutrients & Supplements
- Zinc: 15-30 mg/day. Supports pituitary function and GH synthesis.
- Magnesium Glycinate: 200-400 mg/day. Supports sleep quality and cortisol regulation.
- Vitamin D3: 2000-5000 IU/day. Correlates with optimal IGF-1 levels.
Safety, Interactions & Side Effect Management.
Side Effect Profile
| Side Effect | Severity | Frequency | Management |
|---|---|---|---|
| Intense hunger / appetite | High | Very Common | Plan meals around injection windows. |
| Cortisol elevation | Mild to Moderate | Common | Monitor AM cortisol. |
| Prolactin elevation | Mild to Moderate | Common | Monitor prolactin. |
| Fatigue / lethargy | Mild | Common | Often resolves after the first week. |
| Water retention | Mild | Common | Reduce sodium intake. |
| Facial flushing | Mild | Uncommon | Transient. |
Contraindications
- Absolute: Active malignancy, history of cancer, known hypersensitivity.
- Relative: Pre-existing elevated cortisol or prolactin; active fat loss protocol (hunger response is counterproductive).
Red Flags
Discontinue and consult a physician if:
- Prolactin >25 ng/mL (men) or >30 ng/mL (women).
- AM cortisol consistently elevated above the normal reference range.
Pregnancy, Lactation & Fertility
- Pregnancy: Contraindicated. No human data.
- Lactation: Unknown; use not recommended.
- Fertility: Elevated prolactin can suppress LH/FSH. Monitor if using long-term.
Common Stacks & Combinations.
Synergistic Stacks
- GHRP-6 + CJC-1295 (No DAC): The classic GHRP/GHRH synergy stack. community
- GHRP-6 + BPC-157: For gut health and injury recovery; GHRP-6's gastroprotective properties may complement BPC-157's gut healing effects. community
Anti-Pattern Stacks (What to Avoid)
| Stack | Severity | Rationale |
|---|---|---|
| GHRP-6 + Caloric Deficit | High | The extreme hunger response makes caloric restriction very difficult to maintain. |
| GHRP-6 + Hexarelin | High | Combining two potent GHRPs dramatically increases cortisol and prolactin without proportional GH benefit. |
Body Composition & Training Guide.
Expected Trajectory
| Timeline | Expected Effects |
|---|---|
| Week 1 | Intense hunger, improved sleep quality, possible water retention. |
| Weeks 2-4 | Improved recovery, increased training volume capacity. |
| Weeks 4-12 | Lean mass accrual (best in a caloric surplus). |
Training Contexts
- Bulking/Hypertrophy: GHRP-6 is most effective during bulking phases where the hunger response can be leveraged to increase caloric intake and support muscle growth.
- Fat Loss: Generally not recommended during fat loss phases due to the extreme hunger response.
Storage, Handling & Accessibility.
- Unreconstituted (Lyophilized Powder): Store at 2°C to 8°C, protected from light.
- Reconstituted: Refrigerate at 2°C to 8°C. Use within 30 days.
- Beyond Use Date (BUD): 30 days refrigerated. community
- Accessibility: Not FDA-approved for human use. Available as a research chemical. Banned by WADA.
Bloodwork Monitoring Guide.
Note: Always share peptide usage with your primary care physician. This guide is for informational purposes to facilitate that conversation.
Baseline Panel (Before starting)
- IGF-1
- AM Cortisol
- Prolactin
- Fasting Glucose
Mid-Cycle Panel (Week 6)
- IGF-1 (verify efficacy)
- AM Cortisol (monitor for elevation)
- Prolactin (monitor for elevation)
Post-Cycle Panel (4 weeks after cessation)
- IGF-1
- AM Cortisol
- Prolactin
Comparison to Similar Compounds.
| Compound | GH Potency | Cortisol/Prolactin | Hunger | When to Pick |
|---|---|---|---|---|
| GHRP-6 | Moderate | Moderate | Very High | Bulking phases; appetite stimulation is desired. |
| GHRP-2 | High | Moderate | Moderate | Fat loss or recomposition; more potent GH release. |
| Hexarelin | Highest | High | Moderate | Short-term maximum GH pulse. |
| Ipamorelin | Moderate | Minimal | Minimal | Beginners; long-term use; fat loss. |
Deep Dive (For Advanced Researchers).
Mechanism of Action
GHRP-6 is a synthetic hexapeptide that acts as a potent agonist of the ghrelin receptor (GHSR-1a) [7] in the anterior pituitary and hypothalamus. Binding to GHSR-1a stimulates the synthesis and pulsatile release of endogenous growth hormone. [1] GHRP-6 was the first synthetic GHRP to be identified and studied, and it served as the template for the development of subsequent GHRPs including GHRP-2, Hexarelin, and Ipamorelin. [4]
The intense hunger response from GHRP-6 is mediated by GHSR-1a activation in the hypothalamus, which stimulates the release of neuropeptide Y (NPY) and agouti-related peptide (AgRP), both potent orexigenic (appetite-stimulating) signals. [5]
GHRP-6 has also been shown to have gastroprotective effects in animal models, reducing gastric mucosal injury and promoting healing. [3] This property is thought to be mediated by GHSR-1a activation in the gastrointestinal tract.
Clinical Trial Data
| Study | Design | Key Findings |
|---|---|---|
| Bowers 1984 [1] | Original synthesis study | GHRP-6 was the first synthetic hexapeptide shown to stimulate GH release in vitro and in vivo. |
| Ghigo 1997 [2] | Comparative review | GHRP-6 produced dose-dependent GH release; 1 mcg/kg was the effective dose in adults. |
| Ipamorelin vs GHRP-6 (Raun 1998) [6] | Comparative animal study | Ipamorelin was shown to be as potent as GHRP-6 for GH release but with significantly less cortisol and prolactin elevation. |
Active Metabolites
GHRP-6 is degraded by proteases into smaller inactive peptide fragments. No pharmacologically active metabolites have been identified.
Open Questions
- Gastroprotective mechanism: The gastroprotective effects of GHRP-6 have only been studied in animal models. Human trials are lacking.
- Long-term cortisol effects: The clinical significance of chronic low-grade cortisol elevation from GHRP-6 use has not been formally studied.
Frequently Asked Questions (FAQ).
1. Why does GHRP-6 make me so hungry? GHRP-6 activates GHSR-1a receptors in the hypothalamus, stimulating the release of neuropeptide Y (NPY) and agouti-related peptide (AgRP), both potent appetite-stimulating signals. This hunger response is a direct pharmacological effect of the compound.
2. Is GHRP-6 good for fat loss? Generally not. The extreme hunger response makes caloric restriction very difficult to maintain. GHRP-2 or Ipamorelin are better choices for fat loss protocols.
3. How does GHRP-6 compare to GHRP-2? GHRP-2 is more potent for GH release and produces less hunger. GHRP-6 is preferred when appetite stimulation is a desired benefit (e.g., bulking phases, hardgainers).
4. Does GHRP-6 need to be injected on an empty stomach? Yes. Insulin and somatostatin both blunt the GH pulse. Inject at least 2 hours after your last meal. However, the post-injection hunger window (15-30 minutes after injection) is an ideal time to consume a high-protein meal.
5. Can GHRP-6 help with gut health? Animal studies suggest GHRP-6 has gastroprotective properties. However, human clinical data is lacking. BPC-157 has a much stronger evidence base for gut healing.
6. What is the saturation dose for GHRP-6? Research suggests approximately 1-2 mcg/kg body weight is the maximally effective dose. Doses above this threshold do not produce proportionally greater GH release.
7. Is GHRP-6 detectable in drug testing? Yes. GHRP-6 is banned by WADA and is detectable in urine and blood samples. [9]
International Regulatory Status.
| Country/Region | Regulatory Body | Status | Notes |
|---|---|---|---|
| United States | FDA | Unapproved | Research chemical only. |
| United Kingdom | MHRA | Unapproved | Not licensed for medical use. |
| European Union | EMA | Unapproved | Not approved for human use. |
| Canada | Health Canada | Unapproved | Not approved for human use. |
| Australia | TGA | Restricted | Schedule 4 (Prescription Only Medicine). |
| Global Sport | WADA | Banned | Prohibited at all times under S2 (Peptide Hormones). |
The Decision Tree.
START: Are you a WADA-tested athlete?
├── YES: STOP. GHRP-6 is banned.
└── NO: Are you on a fat loss / caloric deficit protocol?
├── YES: STOP. The extreme hunger response will undermine your deficit. Use Ipamorelin instead.
└── NO: Are you new to peptides?
├── YES: Start with Ipamorelin first; GHRP-6 is not a beginner compound.
└── NO: Is appetite stimulation a benefit for your goals (bulking, hardgainer)?
├── NO: Consider GHRP-2 for more potent GH release without the hunger.
└── YES: GHRP-6 is appropriate. Stack with CJC-1295 (No DAC) for synergy.Schema.org Structured Data.
{
"@context": "https://schema.org",
"@type": "MedicalEntity",
"name": "GHRP-6",
"alternateName": ["Growth Hormone Releasing Peptide-6"],
"description": "The first-generation synthetic hexapeptide GHRP, notable for its potent appetite-stimulating effects and gastroprotective properties in animal models."
}
{
"@context": "https://schema.org",
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Why does GHRP-6 make me so hungry?",
"acceptedAnswer": {
"@type": "Answer",
"text": "GHRP-6 activates GHSR-1a receptors in the hypothalamus, stimulating the release of neuropeptide Y (NPY) and agouti-related peptide (AgRP), both potent appetite-stimulating signals."
}
},
{
"@type": "Question",
"name": "Is GHRP-6 good for fat loss?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Generally not. The extreme hunger response makes caloric restriction very difficult to maintain. GHRP-2 or Ipamorelin are better choices for fat loss protocols."
}
},
{
"@type": "Question",
"name": "How does GHRP-6 compare to GHRP-2?",
"acceptedAnswer": {
"@type": "Answer",
"text": "GHRP-2 is more potent for GH release and produces less hunger. GHRP-6 is preferred when appetite stimulation is a desired benefit."
}
},
{
"@type": "Question",
"name": "Does GHRP-6 need to be injected on an empty stomach?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Yes. Insulin and somatostatin both blunt the GH pulse. Inject at least 2 hours after your last meal."
}
},
{
"@type": "Question",
"name": "Can GHRP-6 help with gut health?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Animal studies suggest GHRP-6 has gastroprotective properties. However, human clinical data is lacking. BPC-157 has a much stronger evidence base for gut healing."
}
},
{
"@type": "Question",
"name": "What is the saturation dose for GHRP-6?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Research suggests approximately 1-2 mcg/kg body weight is the maximally effective dose. Doses above this threshold do not produce proportionally greater GH release."
}
},
{
"@type": "Question",
"name": "Is GHRP-6 detectable in drug testing?",
"acceptedAnswer": {
"@type": "Answer",
"text": "Yes. GHRP-6 is banned by WADA and is detectable in urine and blood samples."
}
}
]
}What we cited.
- Bowers, C. Y., Momany, F. A., Reynolds, G. A., & Hong, A. (1984). On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology, 114(5), 1537-1545. PMID: 6324103
- Ghigo, E., Arvat, E., Muccioli, G., & Camanni, F. (1997). Growth hormone-releasing peptides. European Journal of Endocrinology, 136(5), 445-460. PMID: 9186261
- Sibilia, V., Muccioli, G., Deghenghi, R., Pagani, F., De Luca, V., Rapetti, D., ... & Netti, C. (2006). Evidence for a role of the GHS-R1a receptors in ghrelin inhibition of gastric acid secretion in the rat. Journal of Neuroendocrinology, 18(2), 122-128. PMID: 16420278
- Smith, R. G., Van der Ploeg, L. H., Howard, A. D., Feighner, S. D., Cheng, K., Hickey, G. J., ... & Pong, S. S. (1997). Peptidomimetic regulation of growth hormone secretion. Endocrine Reviews, 18(5), 621-645. PMID: 9331547
- Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., & Matsukura, S. (2001). A role for ghrelin in the central regulation of feeding. Nature, 409(6817), 194-198. PMID: 11196643
- Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., Ankersen, M., & Andersen, P. H. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552-561. PMID: 9849822
- Bowers, C. Y. (1998). Growth hormone-releasing peptide (GHRP). Cellular and Molecular Life Sciences, 54(12), 1316-1329. PMID: 9869414
- Arvat, E., Maccario, M., Di Vito, L., Broglio, F., Benso, A., Gottero, C., ... & Ghigo, E. (2001). Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. Journal of Clinical Endocrinology & Metabolism, 86(3), 1169-1174. PMID: 11238504
- Semenistaya, E., Zvereva, I., Thomas, A., Thevis, M., Krotov, G., & Rodchenkov, G. (2015). Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. Drug Testing and Analysis, 7(11-12), 1036-1043. PMID: 26010999
- Imbimbo, B. P., Mant, T., Edwards, M., Amin, D., Dalton, N., Boutignon, F., ... & Deghenghi, R. (1994). Growth hormone-releasing activity of hexarelin in humans: a dose-response study. European Journal of Clinical Pharmacology, 46(5), 421-425. PMID: 7957536 --- Disclaimer: This document is for informational and harm-reduction purposes only. Always consult a qualified healthcare provider before beginning any peptide protocol.